mushroom retreat oregon

Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat

Silo Wellness Inc. ("Silo Wellness" or "the Company") (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce that on Saturday, March 6, Silo launched its second ketamine-assisted psychedelic wellness retreat on the iconic McKenzie River in Oregon and third psychedelic retreat in 2021.

"Silo Wellness is intent on helping people heal right now," said Chief Executive Officer, Douglas K. Gordon. "We have carefully crafted our Oregon retreat design in light of COVID-19 restrictions to permit participants to enjoy the healing power of nature in conjunction with their physician-led ketamine sessions."

This week's retreat has participants from Florida, Colorado, California, and Oregon. The retreat is designed to focus on nature and the most beautiful product of nature: the mind. During the five-day, six-night retreat, participants will explore waterfalls and experience the exhilarating, refreshing experience of whitewater rafting.The retreat agenda is focused on looking inward at the self during ketamine sessions and on teasing out personal growth through interactive group sessions. The remainder of the retreat is focused on communing with nature. There is a growing body of evidence suggesting potential mental health benefits associated with direct exposure to natural environments. There is also research and anecdotal support suggesting ketamine's potential benefit in addressing mental health issues. It is with these two bodies of research in mind that Silo Wellness has married nature to ketamine therapy in this first-of-its-kind retreat system and North America's first legal psychedelic retreat.

"In essence, our retreats facilitate and integrate the potential epiphanies and insights that are gleaned while using psychedelics," stated Mr. Gordon. "In the case of both our Oregon and Jamaica retreats, nature is a vital component of that integration."

In the United States, ketamine is a Schedule III substance under the Controlled Substance Act, meaning it has a low to moderate potential for physical and psychological dependence. Other examples of Schedule III substances include products containing less than 90 mg of codeine per dosage unit (Tylenol with codeine), anabolic steroids, and testosterone. To obtain ketamine, the prescribing physician must have an active DEA license. The use of ketamine for psychotherapy is a permitted off-label use by a prescribing physician.

All ketamine-assisted retreats of the Company are conducted by a physician that is independent of the Company. The physician qualifies and screens applicants for final acceptance, including any telephone or video consultations deemed necessary by the provider. The physician also provides consultations with each participant to screen for contraindications, appropriate diagnosis (if any), and mental preparedness for the retreat according to his own professional judgment. The physician, if the participant is deemed suitable for ketamine-assisted therapy, will prescribe ketamine to be administered under his medical supervision at the retreat location. The physician also provides pre-event information to attendees. There are individual meetings held virtually and with the group in preparation for the retreat.

Ketamine sessions and related therapy are provided solely by a physician and/or licensed counselor. Those services conducted at the retreat location are provided by the related practitioners and are not provided by or supervised by the Company. The Company does not practice medicine and is not involved with directing any medical care.

ABOUT SILO WELLNESS
The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion.   Silo Wellness intends to introduce new, safe, and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since inception, Silo Wellness' activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness' products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

Further Information: www.silowellness.com

For further information, please contact:

Investor Relations :
David Gdanski
(604) 343-2724
IR@silowellness.com

Media Relations :
Stuart Kirby, VP of Marketing and Communications
press@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION :

This news release contains "forward-looking information" and "forward-looking statements" (collectively, " forward-looking statements ") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the operations and efficacy of the Company's Oregon and Jamaican retreats and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

Compass Pathways to Participate in December Investor Conferences

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

  • 7 th Annual Evercore ISI HealthCONx Conference: Fireside chat at 10:25am ET on December 3, 2024
  • Piper Sandler 36 th Annual Healthcare Conference: Fireside chat at 3:30pm ET on December 4, 2024

A live audio webcast of these events will be accessible here for 30 days following the events.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

  • Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025
  • COMP006 data will now be announced after 26-week time point, expected in the second half of 2026
  • Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30%
  • Cash position of $207 million
  • Conference call October 31 at 8:00 am ET (12:00 pm UK)

Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less

Seelos Announces Second Postponement of its Annual Meeting of Stockholders

Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024 from its originally scheduled date of Friday, September 27, 2024 has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.comSEEL2024 on Monday, November 25, 2024 at 8:00 a.m., Eastern Time . The record date for the Annual Meeting, August 19, 2024 is unchanged and applies to the postponed Annual Meeting.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024.

The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×